You are here

AIDS Vaccine 2012

September 7, 2012
Attending AIDS Vaccine 2012 in Boston? See where and what MHRP will be presenting and plan to attend.

MHRP AIDS Vaccine 2012 Schedule

 

Satellite Sessions

 

Sunday, 9 September 08:30 – 12:00 

HIV Vaccine Efficacy Trials: What does it take?

Westin Hotel, Grand Ballroom A

This session is intended to provide a general overview for our conference, community and journalist scholars and other interested participants of the latest advances in the field and necessary steps to move a vaccine concept into a trial and onward toward licensure.  The session will feature two case studies looking at what comes after an efficacy signal, the many issues along the difficult road to licensure (the RV144 trial) as well as the steps and considerations to plan and execute a phase IIB trials, using HVTN 505 as an example.

Sunday, 9 September 1:30 – 3:30 pm

Efficacy Trials in Design: A Global Perspective

Westin Hotel, Grand Ballroom D

The RV144 HIV vaccine efficacy trial demonstrated that a recombinant canarypox vector boosted with a gp120 conferred 31% efficacy against HIV acquisition compared to placebo. Multiple stakeholders have formed the Pox Protein Public Private Partnership (P5) to build on these results and extend them to other regions of the world. Other vaccine platforms are also in the planning stages for evaluating efficacy along similar timelines as the P5. Several studies are in development, and phase 1/2 studies are expected to begin in 2013, with the potential for a pivotal phase III study and research phase IIb comparisons thereafter in southern Africa, Thailand, and China. This satellite session will update the HIV vaccine community on these various activities and provide a venue for dialogue regarding upcoming efficacy trials.

Monday, Sept. 10 

 

Oral Presentations 

  

Evidence for Env-V2 sieve effect in breakthrough SIVMAC251 infections in rhesus monkeys vaccinated with Ad26/MVA and MVA/Ad26 vectored SIVMAC251 gag/pol/env constructs 

2:15 – 2:30 | Level 2, Ballroom East 

Morgane Rolland 

 

Referral and Access to Care of HIV Prevalent Cases: Experience from the Early Capture HIV Cohort Study in Kampala 

2:30 – 2:45 pm | Room 253 ABC 

Lillian Mutengu 

See the presentation

 

Poster Session 1 

2:45 – 4:00 pm 

 

Immunogenic Selection of HIV-1 MPER Epitopes for Improved Vaccine Design 

Lindsay Wieczorek 

View poster

 

Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian Subtype C gp145 envelope protein for clinical development  

Vicky Polonis 
View poster
  

Incident cases characterization and deep sequencing provide new insight into multiplicity of infection and HIV evolution in very early acute infection 

Gustavo Kijak 

 

Cross-Clade Neutralization of HIV-1 by a Monoclonal Antibody Obtained by Immunization with Liposomes Containing Lipid A and a Synthetic MPER Peptide 

Gary Matyas 

 

Detection of Antibodies to the a4B7 Integrin Binding Site on HIV-1 gp120 V2 Loop Using a Novel Cell Adhesion Assay 

Mangala Rao 

View poster

  

Symposia 

 

Lessons from Clinical Trials 

4:00 – 6:00 pm | Level 2, Room 253 ABC 

COL Jerome Kim 

See the presentation

 

Tuesday, Sept. 11 

 

Plenary 

A New Look at the Transmission Event 

8:30 - 10:00 am | Level 3, Ballroom East 

Viral dynamics and immune response in acute infection and their impact on viral set-point. 

Merlin Robb 
See the presentation

 

Oral Presentations 
  

Safety and Immunogenicity of a randomized Phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 Adjuvanted in Alum or Polyphosphazene 

10:30 – 10:45 am | Room 253 ABC 
LTC Robert O’Connell 

See the presentation

 

Distinct Gene Expression Profiles Assocated with the Susceptibility of Pathogen Specific CD4+ T Cells to HIV-1 Infection 

11:30 – 11:45 am | Room 258 ABC 

Haitao Hu 

See the presentation

 

Poster Session 2 

2:45 – 4:00 pm 
  

Pre-Existing Humoral Immunity in Military Smallpox Vaccines Temporally Effects MCA-Vectored Transgene Expression in Dendritic Cells 

LTC Viseth Ngauy 

Antibody Responses to V2 Loop are Induced by CRF01_A E and not Clade B Envelopes 

MAJ Karasavvas 
  
Posters Session 3 

6:00 – 8:00 pm 
  
Pattern of HIV Risk behavior in a cohort of High-risk women in East Africa 

Hannah Kibuuka 
View poster
  

Early Immune Events During Acute HIV Infection 

Mary Marovich 
  

Neutralization and enhancement of trans infection by erythrocyte-bound HIV with antibodies and complement 

Zoltan Beck 
View poster
  
The Impact of Differences in Viral Entry and Trafficking on the Mechanism of HIV-1 Neutralization 

Camila Macedo 

View poster

 

Wednesday, Sept. 12 
  
Oral Presentation 

T-Follicular Helper Cells in HIV Infection 

8:55 – 9:20 am | Level 3, Ballroom East 

Hendrik Streeck 

See the presentation

    

Rapporteurs 
The Target: How Do We Hit the Virus Where it Hurts?

12:30 – 12:45 pm | Level 3, Ballroom East 

Morgane Rolland   
See the presentation